Could Biological Age Become Pharma's Most Important Biomarker?

Biomarkers that can be used to determine biological age are entering practical healthcare applications, offering new ways to evaluate ageing and health.

New cutting-edge research suggests that the gap between biological and chronological age may provide meaningful insight into future health outcomes. This creates new opportunities for pharmaceutical innovation, clinical development, and preventative medicine.

Image

It’s More Than a Number: Why Biological Age Matters More

Chronological age (the number of birthdays you’ve had) is a convenient way to estimate disease risk, determine treatment eligibility, and stratify participants in clinical trials.

Yet clinicians have always recognised its limitations. Two individuals of the same age can present dramatically different health profiles, levels of resilience, and disease burden.

Researchers are increasingly exploring biological age as a more dynamic measure of physiological health.

Rather than simply recording the passage of time, biological age attempts to measure biomarkers that help quantify how well the body's systems are functioning together.

The latest research offers a strong case that biological age may offer more clinically useful information than chronological age alone.

In a cohort of 2,597 adults followed for almost 10 years, investigators found that individuals whose biological age exceeded their chronological age experienced significantly greater risks of both hospitalisation and all-cause mortality, even after adjusting for established clinical risk factors.

Image

Using Biological Age Biomarkers for Predictive Healthcare

One of the most interesting aspects of the recent study was not its conclusions about how biological age can be better utilised than chronological age, but rather the actual tools used in the identification of such ageing biomarkers.

Rather than relying on expensive specialised molecular testing, the researchers estimated biological age using biomarkers from routine blood chemistry and haematology testing.

The approach demonstrates how existing clinical laboratory data may be transformed into a more comprehensive indicator of physiological ageing without requiring entirely new diagnostic infrastructure.

As for the findings, they too were highly notable. Every additional year that biological age exceeded chronological age was associated with a measurable increase in mortality risk alongside higher rates of hospital admission during follow-up.

Participants whose biological age exceeded their chronological age by approximately three years represented a group with substantially elevated long-term risk, suggesting that even relatively modest biological ageing acceleration may have clinical relevance.

For pharma R&D and clinical development, this reinforces that biomarkers are evolving from diagnostic tools into continuous indicators of health trajectory that represent health outcomes best.

Image

Pharma R&D, Take Note

The implications of biological age and having reliable biomarkers to assess it extend well beyond Longevity research alone.

As pharma continues investment in precision medicine, preventative healthcare, and AI-enabled drug development, biological age biomarkers could become an increasingly valuable endpoint across multiple therapeutic areas.

Clinical trials may benefit from improved participant stratification by distinguishing physiological health from chronological age alone. This could help identify patients who are more likely to respond to interventions, experience adverse events, or demonstrate measurable improvements during treatment.

Similarly, biological age biomarkers may support earlier identification of individuals at increased risk of chronic disease progression before conventional clinical symptoms emerge.

This shift aligns with a broader industry movement towards predictive healthcare, where intervention begins earlier and therapeutic decisions are guided by multidimensional patient data rather than isolated clinical measurements.

Image

Artificial intelligence Is Accelerating Biological Age Science

The latest biological ageing study illustrates the growing role of artificial intelligence in biomarker discovery and ageing research.

Deep learning models are increasingly capable of identifying subtle biological patterns that are difficult for conventional statistical methods to detect.

By integrating multiple laboratory measurements simultaneously, AI can estimate biological ageing with a level of scalability that would have been difficult to achieve using manual analytical approaches.

As AI platforms mature, biological age will become one of several composite digital biomarkers supporting clinical decision-making, alongside genomics, imaging, and real-world health data.

Importantly, these technologies should complement rather than replace clinical judgement. The study's authors acknowledge that biological age remains an evolving research tool requiring validation across broader study populations.

Image

Deep Longevity's Contribution to Longevity Intelligence

This is precisely the area in which innovative health technology company Deep Longevity is helping to advance the scientific understanding of ageing and living longer.

Deep Longevity has become recognised for developing AI-powered biological age models that use diverse biomarker datasets to estimate ageing trajectories.

Their work spans AI-powered biological age clocks, longevity biomarkers, and analytical tools designed to support researchers, healthcare organisations, and pharmaceutical innovators exploring the biology of ageing and Longevity.

Rather than treating ageing simply as an inevitable consequence of time, Deep Longevity's approach seeks to quantify the biological processes underlying health decline, creating opportunities for more personalised interventions and improved preventative strategies.

That expertise is particularly relevant as pharma increasingly investigates therapies targeting ageing-related pathways, multimorbidity, and age-associated chronic disease.

Image

Pharmatica is proud to collaborate with leaders helping shape the emerging ageing and Longevity field.

As part of our commitment to evidence-based pharmaceutical insight, Dr Deepankar Nayak, Deep Longevity’s CEO, serves on the Pharmatica Scientific Council, providing expert guidance on the intersection of artificial intelligence, biomarkers, Longevity science, and pharmaceutical innovation.

Dr Nayak’s expertise strengthens Pharmatica's ability to analyse one of the fastest-evolving areas of biomedical research.

Looking Beyond Lifespan

The greatest value of biological age may ultimately lie not in predicting lifespan but in improving ‘healthspan’.

Healthcare systems worldwide face rising demand driven by ageing populations and increasing chronic disease.

Image

Technologies capable of identifying ageing processes before irreversible decline occurs could help clinicians intervene earlier, support healthier ageing, and potentially reduce healthcare utilisation over time.

While additional research and validation are still required before biological age becomes a routine clinical metric, studies such as this suggest that ageing itself is becoming increasingly measurable rather than simply observable.

For pharmaceutical leaders, that represents a significant strategic opportunity. As biomarkers of biological age mature, they could reshape drug discovery, preventative medicine, patient stratification, and clinical development over the coming decade.

At Pharmatica, we examine the technologies, scientific advances, and strategic partnerships transforming pharmaceutical innovation.

Through contributions from our Scientific Council, including experts such as Dr Deepankar Nayak, we connect emerging research with the practical decisions shaping the future of healthcare.

Pharmatica: Insight. Connection. Impact.